Marc Ditmarsch
Corporate Officer/Principal bei FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Vermögen: - $ am 31.05.2024
Aktive Positionen von Marc Ditmarsch
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01.08.2022 | - |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 01.01.2020 | - |
| Geschäftsführer | 01.01.2020 | - |
Karriereverlauf von Marc Ditmarsch
Ehemalige bekannte Positionen von Marc Ditmarsch
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AstraZeneca BV | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 | 01.01.2016 |
Ausbildung von Marc Ditmarsch
| Vrije Universiteit Amsterdam | Doctorate Degree |
Statistik
International
| Niederlande | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
| AstraZeneca BV |
- Börse
- Insiders
- Marc Ditmarsch
- Erfahrung
